Cubist Systematic Strategies’s Quince Therapeutics QNCX Stock Holding History

Cubist Systematic Strategies’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-150	Closed	-$67K	–	4667
2022 Q2	$67K	Sell	150 -86	-36%	-$60.8K	﹤0.01%	4047
2022 Q1	$292K	Sell	236 -246	-51%	-$335K	﹤0.01%	2857
2021 Q4	$1.22M	Buy	482 +433	+884%	+$2.64M	0.01%	1765
2021 Q3	$896K	Buy	49 +20	+69%	+$318K	0.01%	1613
2021 Q2	$302K	Hold	29	–	–	﹤0.01%	2325
2021 Q1	$211K	Sell	29 -89	-75%	-$640K	﹤0.01%	2436
2020 Q4	$657K	Buy	+118	New	+$1.05M	0.01%	1628

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Cubist Systematic Strategies's QNCX Position: Q3 2022 in Review

Cubist Systematic Strategies sold out of Quince Therapeutics (QNCX) in Q3 2022, closing a stake of 150 shares — an estimated $67K sold.

Cubist Systematic Strategies first reported a position in QNCX in Q4 2020 and held it in 7 quarters. The position peaked at $1.22M in Q4 2021. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

Cubist Systematic Strategies reported no remaining Quince Therapeutics position as of Q3 2022 after selling out during the quarter.
Cubist Systematic Strategies sold 150 Quince Therapeutics shares in Q3 2022, an estimated $67K.
Cubist Systematic Strategies first reported a position in Quince Therapeutics in Q4 2020 and held it in 7 quarters.
Cubist Systematic Strategies's Quince Therapeutics position peaked at $1.22M in Q4 2021.
58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on Cubist Systematic Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.